Monopar Therapeutics (MNPR) Payables (2016 - 2026)
Monopar Therapeutics (MNPR) posted Payables of $2.7 million for Q4 2025, up 6.49% sequentially from $2.6 million in Q3 2025, and up 21.33% YoY from $2.3 million in Q4 2024.
Monopar Therapeutics (MNPR) Payables (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Payables for 10 years, with the latest figure at $2.7 million in Q4 2025.
- Quarterly Payables rose 21.33% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (up 21.33% YoY) and the FY2025 annual result came in at $2.7 million, up 21.33% from the prior year.
- Payables climbed to $2.7 million in Q4 2025 per MNPR's latest filing, from $2.6 million in the prior quarter.
- Over five years, Payables peaked at $3.1 million in Q4 2022 and troughed at $806272.0 in Q1 2021.
- A 5-year average of $1.8 million and a median of $1.7 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2021 and 2024: Payables jumped 253.12% in 2021, then tumbled 56.45% in 2024.
- Over 5 years, Payables stood at $1.6 million in 2021, then jumped by 97.96% to $3.1 million in 2022, then tumbled by 43.83% to $1.8 million in 2023, then gained by 28.28% to $2.3 million in 2024, then advanced by 21.33% to $2.7 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $2.7 million, $2.6 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.02 Mn |
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 3.13 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.19 Mn |
| Mar 31, 2022 | 1.07 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.10 Mn |